Use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions

A technology of activity enhancer and proteoglycan, applied in drug combination, peptide/protein composition, pharmaceutical formulation, etc., can solve problems such as the relationship between biglycan and heart protection that has not been proposed

Inactive Publication Date: 2010-01-20
PHARMAHUNGARY 2000
View PDF13 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0024] Another study suggested that elevated biglycan expression after myocardial infarction was associated with cardiac fibrosis during the healing process, but no relationship between biglycan and cardioprotection was proposed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions
  • Use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions
  • Use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0065]The applicability described above is based on our experimental results demonstrating that increased biglycan activity (preferably from increased biglycan levels) is associated with any atherosclerotic It has an effective prophylactic and / or therapeutic effect in atherosclerotic diseases associated with hardened plaque formation (such as coronary artery sclerosis, carotid artery sclerosis, peripheral arteriosclerosis) and in ischemic diseases such as heart diseases, which Diseases such as acute ischemic heart disease, such as acute myocardial ischemia and / or unstable angina and / or myocardial infarction, and / or cardiac surgical procedures involving myocardial ischemia. Additionally, the cardioprotective effect involves a reduction in infarct size, an improvement in post-infarct myocardial function and / or an improvement in hyperlipidemia-induced cardiac dysfunction. The above-mentioned effects occur in the presence or absence of hyperlipidemia.

[0066] Based on the found ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to the use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions having anti-atherosclerotic and anti-ischemic effect, and to the use of them in methods for preventing and treating the atherosclerotic and ischemid (e.g. cardiac) diseases. The invention also relates to screening methods by which biglycan or enhancers of biglycan activity can be identified.

Description

[0001] The present invention relates to the use of biglycan (biglycan) or a biglycan activity enhancer in the preparation of a pharmaceutical composition with anti-atherosclerosis and anti-ischemic effects, and relates to their use in atherosclerosis Use in methods of prevention and treatment of sclerosis and ischemic (eg heart) diseases. The present invention also relates to screening methods that enable the identification of biglycan or enhancers of biglycan activity. Background of the invention [0002] Biglycan and its role in the cardiovascular system [0003] Biglycan is a member of the small leucine-rich proteoglycan (SLRP) family characterized by the presence of repetitive leucine-rich amino acid motifs [Fisher, L.W., Termine, J.D., and Young , M.F.: Deduced protein sequence of bone small proteoglycan I (biglycan) shows homology with proteoglycan II (decorin) and several nonconnective tissue proteins in a variety of species. J. Biol. Chem. 264, 4571-4576 (1989)]. [...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/60A61P9/10A61K38/17
CPCG01N2333/4722G01N2800/7019A61K38/1709A61K31/60G01N33/5023G01N2800/323A61P43/00A61P9/10
Inventor M·尚陶S·贡达E·拜赖茨基P·费迪南迪T·琼特
Owner PHARMAHUNGARY 2000
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap